600867 Tonghua Dongbao Pharmaceutical
- 10.59
- +0.41+4.03%
Tonghua Dongbao Pharmaceutical News
Tonghua Dongbao (600867.SH) announced first-quarter results, net profit of 215 million yuan, a year-on-year decrease of 14.28%
Tonghua Dongbao (600867.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 5.9 during the reporting period...
Guojin Securities: Continued increase in domestic insulin share is expected to drive continued growth in performance
Since May 2022, national special insulin collection has been launched in various provinces and cities. While the price of insulin products has declined, the domestic substitution process has greatly accelerated.
Tonghua Dongbao (600867.SH): Clinical approval for injectable THDBH120 weight loss indications
Tonghua Dongbao (600867.SH) announced that Dong****ing (Hangzhou) Biomedical Co., Ltd., a wholly-owned subsidiary of the company...
Express News | Tonghua Dongbao: GLP-1 /GIP dual-target receptor agonist weight loss application approved for clinical use
Huatai Securities: National insulin collection contract renewal and bid opening, leading domestic companies are expected to maintain gross margin above 80%
The Zhitong Finance App learned that Huatai Securities released a research report stating that on April 23, the national insulin collection contract was renewed and opened. The current collection volume was about 60% of the country's total demand, and the overall price was reduced by about 3.8%, and the bid period was until the end of '27. The rules for this collection were gentle, and it was stipulated that 92% of the products were selected. Among them, Ganli Pharmaceutical, Hefei Tianmai, and Yifan Biotech rose across the board, while Tonghua Dongbao dropped moderately and all were selected in Class A. The current collection renewal price favors leading domestic companies. The gross margin of leading domestic insulin companies is expected to remain above 80%; at the same time as the prices of some domestic companies are rising
Tonghua Dongbao (600867.SH): Participates in the national centralized drug procurement (insulin special continuation) to be selected
Gelonghui, April 23 | Tonghua Dongbao (600867.SH) announced that on April 23, 2024, the company participated in the national centralized drug procurement (insulin special continuation) declaration process organized by the State Organization's Centralized Drug Procurement and Use Joint Procurement Office (referred to as the “Joint Procurement Office”). Company human insulin injection, sperm protein human insulin injection, argentine human insulin mixed injection (30R), sperm protein human insulin mixed injection (40R), sperm protein human insulin mixed injection (50R), glargine insulin injection, menthong insulin injection, menthong insulin 3
Express News | Tonghua Dongbao: Multiple specification products to be selected for centralized procurement
Express News | Tonghua Dongbao Insulin won the bid for successive insulin purchases at the lowest price
Tonghua Dongbao Insulin successively purchased 6 competitive products and lowered the bid prices for all
Gelonghui, April 23 | According to the Science and Technology Innovation Board Daily, we learned at the special insulin procurement site on the 23rd that the prices for the subsequent procurement of Tonghua Dongbao human insulin injection, sperm protein human insulin mixed injection (30R), mendong insulin injection, insulin glargine injection, and Mendong insulin 30 injection were all bid. The prices for the 6 products corresponding to the 3ml:300 unit (refill) specifications were 25.93 yuan, 25.93 yuan, 25.93 yuan, respectively. 23.98 yuan, 63.33 yuan, 23.98 yuan Of these, the top 5 products
Express News | At the insulin collection renewal site, Tonghua Dongbaoshen's offer leaked out
Is Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Latest Stock Performance A Reflection Of Its Financial Health?
Tonghua Dongbao Pharmaceutical's (SHSE:600867) stock is up by a considerable 10% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is th
Tonghua Dongbao (600867) 2023 Report Review: Rapid Release of New Insulin Products, Innovative Drugs, and Steady Progress in Internationalization
Matters: Recently, the company disclosed its 2023 annual report. The company's revenue in 2023 was 3,075 billion yuan (+10.7%), the mother was 1.17 billion yuan (-26.2%), after deducting not 1.17 billion yuan (+38.9%)
Tonghua Dongbao (600867): Rapid growth in insulin sales, steady progress in R&D and internationalization
Tonghua Dongbao announced its 2023 results. In 2023, the company achieved operating income of 3,075 billion yuan, +10.7% year over year; net profit to mother was 1,168 billion yuan, -26.2% year over year; net profit not attributable to mother11
Tonghua Dongbao (600867): Performance is in line with expectations, further consolidating its leading position in insulin
The 2023 results are in line with our expectations Tonghua Dongbao announced 2023 results: 2023 operating income of RMB 3,075 billion, up 10.69% year on year; net profit to mother of RMB 1,168 billion (per share)
Tonghua Dongbao (600867): Innovation in stable insulin dosage and continuous breakthroughs in overseas travel
The impact of collection was gradually cleared up, and performance achieved steady growth. In 2023, the company achieved operating income of 3,075 billion yuan, an increase of 10.7% over the previous year; achieved net profit of 1,168 billion yuan, a year-on-year decrease of 26.2%; realized deductions
Tonghua Dongbao Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) came out with a strong set of annual numbers that could potentially lead to a re-rate of the stock. Results were good overall, w
Tonghua Dongbao (600867): The rapid growth of third-generation insulin accelerates the internationalization of insulin
Incident: The company released its 2023 annual report, achieving operating income of 3.08 billion yuan (+10.7%), net profit attributable to shareholders of the parent company of 1.37 billion yuan (-25.4%), and deductions attributable to shareholders of listed companies are not regular
Tonghua Dongbao (600867.SH): Net profit in 2023 fell 26.17% year-on-year, and plans to distribute 2.5 yuan for 10 shares
Gelonghui, March 28 | Tonghua Dongbao (600867.SH) released its 2023 annual report. Operating revenue was 3,075 billion yuan, up 10.69% year on year, net profit was 1,168 billion yuan, down 26.17% year on year, after deducting non-net profit of 1,168 billion yuan, up 38.88% year on year, with basic earnings of 0.59 yuan per share. A cash dividend of 2.5 yuan is distributed to all shareholders for every 10 shares.
Tonghua Dongbao (600867): Steady revenue growth in 2023
Revenue growth was steady in 2023, maintaining that the buy-rating company released its annual report for the year 23 on 3/28, achieved revenue of 3.08 billion yuan (+10.7% yoy) in 23, and net profit of 1.17 billion yuan (-26.2 million yuan) in fiscal year 23
Tonghua Dongbao (600867): Overall increase in insulin sales, steady progress in R&D projects
Brief review of the incident On March 28, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 3,075 billion yuan, an increase of 11% over the previous year; realized net profit of 1,168 billion yuan, compared with the same period last year
Analysis
Price Target
No Data
